Meriofert Kit (Follicle-Stimulating Hormone, Luteinising Hormone)

FSH binds to receptors on ovarian granulosa cells, promoting follicle growth and estradiol synthesis, while LH binds to receptors on theca and luteal cells, triggering final follicle maturation, ovulation and luteinisation. Together they coordinate the hormonal cascade required for successful oocyte release and preparation of the endometrium.

The dose of Meriofert Kit is individualized by the prescribing clinician based on the patient’s age, ovarian reserve, treatment protocol and response to monitoring. The prescriber determines the exact amount, frequency and duration of subcutaneous injections for each treatment cycle.

Meriofert Kit is intended for use before conception to facilitate ovulation. Its safety in established pregnancy or while breastfeeding has not been established, and it should not be used during those periods unless specifically directed by a qualified specialist.

To order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain where required) and necessary import documentation.

Meriofert Kit combines both FSH and LH in a single injectable formulation, offering a convenient alternative to using separate FSH‑only and LH‑only preparations. This dual‑action product can simplify dosing schedules and may improve synchronization of follicular development compared with single‑component gonadotropins.

Meriofert Kit must be stored refrigerated at 2‑8 °C, protected from light, and must not be frozen or shaken. Before use, allow the vial to reach room temperature for a few minutes, and inspect for particulate matter or discoloration. Follow aseptic technique for subcutaneous injection.

Meriofert Kit is supplied as a sterile solution for subcutaneous injection. The prescriber will instruct the patient on the injection site (typically the abdomen or thigh), rotation of sites, and the exact volume to administer using a sterile needle and syringe. Injections are usually given once daily or as per the specific stimulation protocol.

The most serious risks include severe ovarian hyperstimulation syndrome, which can cause fluid shifts, thromboembolic events, and in rare cases, ovarian torsion. Allergic reactions, including anaphylaxis, and multiple pregnancy are also significant concerns that require prompt medical attention.

Meriofert Kit should not be used in individuals with known hypersensitivity to any gonadotropin component, in patients with active ovarian cysts, uncontrolled thyroid disease, or in women who are already pregnant. It is also contraindicated in those with severe ovarian hyperstimulation syndrome from a previous cycle.